Respiratory infections in immunocompromised patients

Current Opinion in Pulmonary Medicine

Volumn 5, Issue 3, 1999, Pages 168-173

  Barry, Simon M ^a   Lipman, Marc C I ^a   Johnson, Margaret A ^a   Prentice, H Grant ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AIDS RELATED COMPLEX; COMORBIDITY; FEMALE; HISTOCOMPATIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; INCIDENCE; MALE; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SURVIVAL RATE; TUBERCULOSIS; UNITED KINGDOM;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY; TUBERCULOSIS;

EID: 0033128521     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199905000-00008     Document Type: Article

References (50)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al: Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Statten GA, et al and the HIV Outpatient Study Investigators: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
3. Kumar SD, Krieger BP: CD4 lymphocyte counts and mortality in AIDS patients requiring Mechanical ventilator support due to Pneumocystis carinii pneumonia. Chest 1998, 113:430-433.
4. Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD and the Outpatient (HOPS) Investigators: Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:182-188. A very large study with statistically significant findings.
5. Douglas R, Spelman D, Czarny D, O'Hehir RE: Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulphamethoxazole. Clin Infect Dis 1997, 25:1480.
6. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, et al.: Pneumocystis carinii mutations associated with sulpha and sulphone prophylaxis failures in AIDS patients. AIDS 1998, 12:873-878.
7. Mei O, Gurunathan S, Masur H, Kovacs JA: Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene [letter]. Lancet 1998, 351:1631-1632.
8. Jacobson MA, French M: Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998, 12(suppl A):157-163.
9. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998, 12:1815-1822. This study provides useful clinical guidance on when to stop opportunistic infection chemoprophylaxis in patients receiving HAART.
10. Selwyn PA, Pumerantz AS, Durante PG, Gourevitch MN, Boiselle PM, Elmore JG: Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV infected patients. AIDS 1998, 12:885-893.
11. Karstaedt AS, Jones N, Khoosal M, Crewe-Brown HH: The bacteriology of pulmonary tuberculosis in a population with a high human immunodeficiency virus seroprevalence. Int J Tuberc Lung Dis 1998, 2:312-316.
12. Spellman CW, Matty KJ, Weis SE: A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. AIDS 1998, 12:191-195.
13. Mitchison DA: How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998, 2:10-15.
14. De Cock KM, Wilkinson D: Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. Lancet 1995, 346:675-677.
15. Wilkinson D, Squire SB, Garner P: Effect of preventative treatment for tuberculosis in adults infected with HIV: Systematic review of randomised placebo controlled trials. BMJ 1998, 317:625-629.
16. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala B, et al: Twice weekly tuberculosis preventative therapy in HIV infection in Zambia. AIDS 1998, 12:2447-2457.
17. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:786-792.
18. Saple DG, Maniar JK, Desai SA: Efficacy of rifampicin and isoniazid prophylaxis for tuberculosis for HIV/AIDS, Mumbai, India [abstract P248]. AIDS 1998 12 (suppl 4):S79.
19. Centers for Disease Control and Prevention: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998, 47:RR-20. Comprehensive, informative, and up-to-date review of the subject.
20. Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations 1998. Thorax 1998, 53:536-548.
21. Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Crit Care Med 1998, 158:157-161.
22. Chien JW, Johnson JL: Paradoxical reactions in HIV and pulmonary TB. Chest 1998, 114:933-936.
23. Autran B, Garcelain G, Li TS, Blanc C, Malthez D, Tubiana R, et al.: Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
24. Johnson BJ, Bekker LG, Rickman R, Brown S, Lessor M, Rees S, et al.: rhulL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimes and placebo. Tuberc Lung Dis 1997, 78:195-203. This article describes an interesting new approach using immunostimulation.
25. Rom WN, Yie TA, Tchou-Wong KM: Development of a suicide gene as a novel approach to killing Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997, 156:1993-1998.
26. Gladwin MT, Plorde JJ, Martin TR: Clinical application of the Mycobacterium tuberculosis direct test. Chest 1998, 114:317-323.
27. Gillespie SH: New polymerase chain reaction-based diagnostic techniques for bacterial respiratory infection. Curr Opin Infect Dis 1998, 11:133-138.
28. Komanduri VK, Viswanathan MN, Weider ED, Schmidt DK, Bredt BM, Jacobsen MA, McCune JM: Restoration of cytomegalovirus-specific CD4 T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998, 4:953-956.
29. Woitas RP, Rockstroh JK, Theisen A, Leutner C, Sauerbruch T, Spengler U. Changing role of invasive aspergillosis in AIDS: a case control study. J Infect 1998, 37:116-122.
30. Mylonakis E, Barlam TF, Flanigan T, Rich JD: Pulmonary aspergillosis and invasive disease in AIDS. Chest 1998, 114:251-262. A literature review of 342 cases of "definite" and "probable" invasive pulmonary aspergillosis. Presenting clinical symptoms and management are covered.
31. Wallace JM, Lim R, Browdy BL, Hopewell PC, Glassroth J, Rosen MJ, et al.: Risk factors and outcomes associated with identification of aspergillus in respiratory specimens from persons with HIV disease. Chest 1998, 114:131-137.
32. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milipied NJ, et al.: Long-Term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997, 19:129-133.
33. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, Emery VC: Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21:597-605. This article shows how CMV viral load by quantitative PCR is the most significant risk factor for CMV disease.
34. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al.: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
35. Pawson R, Moore J, Potter M, Geretti AM, Griffiths P, Prentice HG: Treatment Of CMV infections after allogeneic BMT with combination of half-dose ganciclovir plus foscarnet [abstract]. Blood 1998, 92(suppl 1):1156.
36. Walter EA, Greenburg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
37. Grundy J: Current antiviral therapy fails to prevent the pro-inflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack. Monogr Virol 1998, 21:67-89. Informative article on the immunomodulatory effects of CMV and its interaction with the immune response.
38. Ljungman P: Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant 1998, 21 (suppl 2):72-74.
39. McColl MD, Corser RB, Brenner J, Chopra R: Respiratory syncytial virus infection in adult BMT patients: effective therapy with short duration nebulised ribavarin. Bone Marrow Transplant 1998, 21:423-425.
40. Kibbler CC, Prentice HG: A reappraisal of current approaches to the management of fungal infections in neutropenic patients. Curr Opin Infect Dis 1998, 11:397-400. Concise review covering recent approaches to a difficult area of clinical medicine.
41. Berger LA: Imaging in the diagnosis of infections in immunocompromised patients. Curr Opin Infect Dis 1998, 11:431-436.
42. Brown MJ, Worthy SA, Flint JDA, Muller NL: Invasive aspergillosis in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage. Clin Radiol 1998, 53:255-257. Important study showing how CT appearances can predict the chance of a positive result on BAL testing for aspergillus.
43. Einsele H, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, et al.: Detection And identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997, 35:1353-1360.
44. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl J Med 1998, 338:1741-1751. A good review covering a broad topic.
45. Stephane F, Fajac A, Grenet D, Honderlick P, Ricci S, et al.: Predictive value of cytomegalovirus DNA detection by polymerase chain reaction in blood and bronchoalveolar lavage in lung transplant patients. Transplantation 1997, 63:1430-1435.
46. Roberts TC, Brennan DC, Buller RS, Gaudreault-Keener M, et al.: Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant patients. J Infect Dis 1998, 178:626-635.
47. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC: Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997, 176:1484-1490. Study showing the importance of quantitative PCR in predicting CMV disease following liver transplant and the effect of steroids in lowering the CMV viral load at which disease occurs.
48. Segal BH, Sneller MC: Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997, 23:219-237. Excellent and wide-ranging review covering the basic science of immunosuppressive therapy along with clinical aspects.
49. Carrock Sewell WA, Webster ADB: Infection in patients with congenital immune deficiencies. Curr Opin Infect Dis 1998, 11:419-423. A good review of more esoteric causes of immunosuppression.
50. Ottenhoff T, Kumararatne D, Casanova J-L: Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol Today 1998, 19:491-494.